

Lori M Minasian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2620610/publications.pdf>

Version: 2024-02-01

40
papers

3,582
citations

304368

22
h-index

276539

41
g-index

41
all docs

41
docs citations

41
times ranked

5714
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244.	3.0	689
2	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051.	3.4	581
3	Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. <i>Journal of the National Cancer Institute</i> , 2019, 111, 245-255.	3.0	294
4	Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju129-dju129.	3.0	245
5	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2627-2633.	0.8	184
6	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3014-3022.	0.8	170
7	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.	5.1	167
8	“When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 244-257.	3.0	116
9	Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. <i>Journal of Clinical Oncology</i> , 2014, 32, 3275-3283.	0.8	115
10	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 1474-1486.	0.8	102
11	Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3231-3239.	0.8	100
12	New strategies in ovarian cancer treatment. <i>Cancer</i> , 2019, 125, 4623-4629.	2.0	92
13	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , 2015, 33, 1910-1917.	0.8	83
14	Quality-of-Life Assessment in the Symptom Management Trials of the National Cancer Institute-Supported Community Clinical Oncology Program. <i>Journal of Clinical Oncology</i> , 2005, 23, 591-598.	0.8	73
15	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	0.8	59
16	Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections. <i>Clinical Cancer Research</i> , 2018, 24, 1780-1784.	3.2	53
17	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. <i>Journal of Clinical Oncology</i> , 2018, 36, 3120-3125.	0.8	45
18	A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. <i>Cancer</i> , 1995, 75, 2251-2257.	2.0	42

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life and Symptom Management Research Sponsored by the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2007, 25, 5128-5132.	0.8	40
20	The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2016, 143, 611-616.	0.6	30
21	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	3.0	25
22	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	1.9	23
23	Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 606.e1-606.e9.	0.7	19
24	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. <i>JACC: CardioOncology</i> , 2019, 1, 105-113.	1.7	17
25	A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. <i>Respiratory Research</i> , 2015, 16, 35.	1.4	16
26	Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials. <i>Cancer Medicine</i> , 2018, 7, 2951-2959.	1.3	16
27	What Keeps Patients Out of Clinical Trials?. <i>JCO Oncology Practice</i> , 2020, 16, 125-127.	1.4	16
28	Chemotherapy-induced peripheral neuropathy: Identifying the research gaps and associated changes to clinical trial design. <i>Cancer</i> , 2020, 126, 4602-4613.	2.0	14
29	Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 47-59.	3.0	12
30	Reporting of health-related quality of life endpoints in National Cancer Institute-supported cancer treatment trials. <i>Cancer</i> , 2020, 126, 2687-2693.	2.0	11
31	Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 512-514.	1.1	11
32	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	2.2	11
33	Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors. <i>American Journal of Medicine</i> , 2020, 133, 723-732.	0.6	9
34	Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 271-282.	0.7	8
35	Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. <i>Cancer Prevention Research</i> , 2021, 14, 205-214.	0.7	4
36	Multilevel modeling and value of information in clinical trial decision support. <i>BMC Systems Biology</i> , 2014, 8, 6.	3.0	3

#	ARTICLE	IF	CITATIONS
37	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. <i>Cancer Epidemiology</i> , 2018, 55, 117-122.	0.8	3
38	Breast cancer risk prediction models and subsequent tumor characteristics. <i>Breast Cancer</i> , 2020, 27, 662-669.	1.3	3
39	Ongoing Use of Data and Specimens From National Cancer Instituteâ€“Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. <i>Seminars in Oncology</i> , 2015, 42, 748-763.	0.8	2
40	Report from an NCI Roundtable: Cancer Prevention in Primary Care. <i>Cancer Prevention Research</i> , 2022, 15, 273-278.	0.7	1